Biotech Analysts, along with Dr. Murray Stein, Professor at the University of California, discuss Neuphoria’s near-term Phase 3 AFFIRM-1 data in social anxiety disorder (SAD) with BNC210 on an Analyst/Industry conference call to be held on October 6 at 3 pm. Webcast Link
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP:
- Neuphoria Therapeutics: Strong Cash Position and Promising Pipeline Drive Buy Rating
- Neuphoria Therapeutics price target raised to $35 from $18 at Maxim
- Neuphoria Therapeutics completes target enrollment in Phase 3 AFFIRM-1 trial
- Neuphoria Therapeutics initiated with a Buy at Lucid Capital
- Neuphoria Therapeutics’s BNC210: Buy Rating Affirmed Ahead of Pivotal Phase 3 AFFIRM-1 Trial